Vaxart Announces Publication in Vaccines of Preclinical Data Supporting the Potential of its Mucosal Vaccine Technology Platform in Enabling Therapeutic Vaccination for HPV-Related Cervical Dysplasia

Read also

Pharma Tariffs

Pharma Tariffs Back In Spotlight On New Trump Threat

FDA approves Lilly’s Inluriyo

FDA approves Lilly’s Inluriyo to treat advanced breast cancer

Synaffix and Qurient

Synaffix and Qurient enter licensing deal for dual-payload ADC

Biotech Stocks Facing

Biotech Stocks Facing FDA Decision In October 2025